Itrabat 100 Capsule contains Itraconazole 100 mg, a broad-spectrum antifungal agent belonging to the triazole class. It is indicated for the treatment of various systemic and superficial fungal infections, including aspergillosis, blastomycosis, histoplasmosis, onychomycosis, and candidiasis. Itraconazole exerts its antifungal effect by inhibiting the cytochrome P450-dependent enzyme lanosterol 14-α-demethylase, which is essential for ergosterol synthesis, a key component of fungal cell membranes. This disruption leads to increased membrane permeability and ultimately fungal cell death. Itrabat 100 Capsule is administered orally and demonstrates good bioavailability, especially when taken with food, enhancing absorption. The drug is extensively metabolized in the liver via the CYP3A4 pathway, and its elimination half-life allows for once or twice daily dosing depending on the infection severity and clinical response. Common adverse effects include gastrointestinal disturbances, headache, and rash, while serious side effects may involve hepatotoxicity and cardiac issues such as congestive heart failure in predisposed patients. Caution is advised when co-administering with drugs metabolized by CYP3A4 due to potential interactions. Itrabat 100 Capsule should be used under medical supervision with appropriate monitoring for efficacy and safety.